These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 30885777)

  • 1. Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?
    Ling DC; Sutera PA; Iarrobino NA; Diego EJ; Soran A; Johnson RR; Bhargava R; Champ CE; Beriwal S
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):869-876. PubMed ID: 30885777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment.
    Jwa E; Shin KH; Kim JY; Park YH; Jung SY; Lee ES; Park IH; Lee KS; Ro J; Kim YJ; Kim TH
    Cancer Res Treat; 2016 Oct; 48(4):1363-1372. PubMed ID: 26910473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D; Jie Q; Wu Y; Xu Y; Hong W; Meng X
    World J Surg Oncol; 2022 Sep; 20(1):326. PubMed ID: 36175898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience.
    Chen AM; Meric-Bernstam F; Hunt KK; Thames HD; Oswald MJ; Outlaw ED; Strom EA; McNeese MD; Kuerer HM; Ross MI; Singletary SE; Ames FC; Feig BW; Sahin AA; Perkins GH; Schechter NR; Hortobagyi GN; Buchholz TA
    J Clin Oncol; 2004 Jun; 22(12):2303-12. PubMed ID: 15197191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locoregional recurrence of breast cancer in patients treated with breast conservation surgery and radiotherapy following neoadjuvant chemotherapy.
    Min SY; Lee SJ; Shin KH; Park IH; Jung SY; Lee KS; Ro J; Lee S; Kim SW; Kim TH; Kang HS; Cho KH
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e697-705. PubMed ID: 21129858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy].
    Sun GY; Wang SL; Tang Y; Jin J; Song YW; Liu YP; Wang WH; Fang H; Chen SY; Ren H; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):352-358. PubMed ID: 29860762
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index.
    Ishitobi M; Ohsumi S; Inaji H; Ohno S; Shigematsu H; Akiyama F; Iwase T; Akashi-Tanaka S; Sato N; Takahashi K; Oura S
    Cancer; 2012 Sep; 118(18):4385-93. PubMed ID: 22252882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival.
    Precht LM; Lowe KA; Atwood M; Beatty JD
    Breast J; 2010; 16(4):362-8. PubMed ID: 20443786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer.
    Vargo JA; Beriwal S; Ahrendt GM; Soran A; Johnson RR; McGuire K; Bhargava R
    Oncology; 2011; 80(5-6):341-9. PubMed ID: 21791944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype.
    Kim HJ; Han W; Yi OV; Shin HC; Ahn SK; Koh BS; Moon HG; You JH; Son BH; Ahn SH; Noh DY
    Breast Cancer Res Treat; 2011 Nov; 130(2):499-505. PubMed ID: 21853352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy.
    Hattangadi-Gluth JA; Wo JY; Nguyen PL; Abi Raad RF; Sreedhara M; Niemierko A; Freer PE; Georgian-Smith D; Bellon JR; Wong JS; Smith BL; Harris JR; Taghian AG
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1185-91. PubMed ID: 21601377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer.
    Parikh RR; Housman D; Yang Q; Toppmeyer D; Wilson LD; Haffty BG
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1056-63. PubMed ID: 18676094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the subtype on local recurrence risk of breast cancer with or without radiation therapy.
    Wickberg Å; Magnuson A; Holmberg L; Adami HO; Liljegren G
    Breast; 2018 Dec; 42():54-60. PubMed ID: 30176553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: application and outcomes.
    Migdady Y; Sakr BJ; Sikov WM; Olszewski AJ
    Breast; 2013 Oct; 22(5):793-8. PubMed ID: 23489757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
    Jin X; Jiang YZ; Chen S; Yu KD; Shao ZM; Di GH
    Oncotarget; 2015 Apr; 6(11):9600-11. PubMed ID: 25826079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer subtype and distant recurrence after ipsilateral breast tumor recurrence.
    Ishitobi M; Okumura Y; Arima N; Yoshida A; Nakatsukasa K; Iwase T; Shien T; Masuda N; Tanaka S; Tanabe M; Tanaka T; Komoike Y; Taguchi T; Nishimura R; Inaji H
    Ann Surg Oncol; 2013 Jun; 20(6):1886-92. PubMed ID: 23292516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.